2018 Operational Update

Tim Edwards appointed as Executive Chairman KA2237 and KA2507 – innovative, molecular-targeted anti-cancer therapeutics – progressing in Phase I clinical trials for the treatment of cancer, with clinical responses confirmed for KA2237 in patients with refractory B-cell lymphomas Research and development activities on a novel, differentiated HDAC6 inhibitor series progressing well, with preclinical development candidate […]

Genesis 2018

13 December 2018 Genesis 2018 London, UK

BIO-Europe

5-7 November 2018 BIO-Europe Copenhagen, Denmark & Malmö, Sweden

NCRI Cancer Conference

4-6 November 2018 NCRI Cancer Conference Glasgow, UK

BIA UK Bioscience Forum

18 October 2018 BIA UK Bioscience Forum London, UK

ELRIG Drug Discovery 2018

9-10 October 2018 ELRIG Drug Discovery 2018 London, UK

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins JCI Insight 2018, 3(11), e120631

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation.

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation. Ellis J, Neil D, Inston N, Jenkinson E, Drayson M, Hampson P, Shuttleworth S, Ready A, Cobbold M. Transplantation 2016, 100(8), 1667

AACR Annual Meeting 2018

14-18 April 2018 AACR Annual Meeting 2018 Chicago, USA Stephen Shuttleworth attending